A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines. While …
Claims Handling Breakdowns From LA Wildfires One Year on
It’s been more than a year since the Palisades and Eaton Fires in Los Angeles, and attorneys who work in first‑party property claims are still
